Treatment of Kawasaki disease with anti-TNF antibodies.

作者信息

Levin Michael, Burgner David

机构信息

Section of Paediatrics, Faculty of Medicine, Imperial College London, London W2 1PG, UK.

Murdoch Childrens Research Institute, VIC, Australia; University of Melbourne, VIC, Australia; Monash Children's Hospital, VIC, Australia.

出版信息

Lancet. 2014 May 17;383(9930):1700-3. doi: 10.1016/S0140-6736(14)60131-8. Epub 2014 Feb 24.

DOI:10.1016/S0140-6736(14)60131-8

PMID:24572998

Abstract

摘要

相似文献

Treatment of Kawasaki disease with anti-TNF antibodies.

Lancet. 2014 May 17;383(9930):1700-3. doi: 10.1016/S0140-6736(14)60131-8. Epub 2014 Feb 24.

Inflammation: Phase III trial of infliximab in Kawasaki disease.

Nat Rev Cardiol. 2014 Apr;11(4):188. doi: 10.1038/nrcardio.2014.25. Epub 2014 Mar 11.

Vasculitis syndromes: phase III trial of infliximab in Kawasaki disease.

Nat Rev Rheumatol. 2014 Apr;10(4):198. doi: 10.1038/nrrheum.2014.42. Epub 2014 Mar 11.

Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?

Pediatr Cardiol. 2013 Oct;34(7):1756. doi: 10.1007/s00246-013-0731-3. Epub 2013 Jun 15.

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.

Infliximab treatment for refractory Kawasaki syndrome.

J Pediatr. 2005 May;146(5):662-7. doi: 10.1016/j.jpeds.2004.12.022.

Efficacy of infliximab in long-lasting refractory Kawasaki disease.

Clin Exp Rheumatol. 2006 Jul-Aug;24(4):453.

Infliximab for Kawasaki syndrome.

J Pediatr. 2006 Sep;149(3):426; author reply 426. doi: 10.1016/j.jpeds.2005.07.039.

Infliximab treatment in refractory Kawasaki syndrome.

Indian J Pediatr. 2008 May;75(5):521-2. doi: 10.1007/s12098-008-0084-8. Epub 2008 Jun 8.

Infliximab for the treatment of Kawasaki disease.

Pediatr Int. 2018 Sep;60(9):775. doi: 10.1111/ped.13663.

引用本文的文献

Clinical characteristics of Kawasaki disease with pulmonary radiographic abnormalities and its impact on the incidence of coronary artery lesions: a randomized retrospective cohort study.

Front Pediatr. 2025 Feb 6;13:1506735. doi: 10.3389/fped.2025.1506735. eCollection 2025.

Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease.

Pediatr Rheumatol Online J. 2022 Dec 22;20(1):119. doi: 10.1186/s12969-022-00783-7.

Clinical Proteomics Profiling for Biomarker Identification Among Patients Suffering With Indian Post Kala Azar Dermal Leishmaniasis.

Front Cell Infect Microbiol. 2020 May 27;10:251. doi: 10.3389/fcimb.2020.00251. eCollection 2020.

Clinical characteristics of Kawasaki disease complicated with Mycoplasma pneumoniae pneumonia: A retrospective study.

Medicine (Baltimore). 2020 May;99(19):e19987. doi: 10.1097/MD.0000000000019987.

Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.

Sci Rep. 2017 Mar 6;7:43732. doi: 10.1038/srep43732.

Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.

Chin Med J (Engl). 2016 Apr 20;129(8):922-8. doi: 10.4103/0366-6999.179801.

Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

J Pediatr Pharmacol Ther. 2015 May-Jun;20(3):163-77. doi: 10.5863/1551-6776-20.3.163.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验